RET and hypertensive disorder: Since other molecular markers such as RET/PTC and Galectin-3 which were initially thought to be only expressed in PTC are now seen in some benign lesions of the thyroid.[25] Therefore, at present it is advisable to diagnose these tumors as HTN and relay to clinicians that this tumor behaves in benign fashion.